Litcius/Paper detail

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Enrique Grande, José Ángel Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier García del Muro, Se Hoon Park, Ugo De Giorgi, B. Yа. Alekseev, Marina Mencinger, Kouji Izumi, Fabio A.B. Schutz, Javier Puente, Jian‐Ri Li, Peter H. O’Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, FabioIa Bene-Tchaleu, Sandrine Bernhard, Chooi Lee, Ian D. Davis, Matthew D. Galsky

2023The Lancet Oncology56 citationsDOI

Topics & Concepts

Metastatic Urothelial CarcinomaAtezolizumabMedicineChemotherapyPlaceboOncologyInternal medicineUrothelial carcinomaCarcinomaUrologyCancerBladder cancerImmunotherapyPathologyPembrolizumabAlternative medicineBladder and Urothelial Cancer TreatmentsCholangiocarcinoma and Gallbladder Cancer StudiesIntraperitoneal and Appendiceal Malignancies